Status: Recruiting
HER-2 B Cell Peptide Vaccine
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.
Participants needed: 42
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Pravin T.P KaumayaUpdated: Aug 24, 2025Locations: 1
Eligibility criteria
For the extension cohort to be conducted at the IUSCCC (N=12), patients with his... [+20]
Patients with tumors that are negative for HER-2 expression based on IHC of 0 AN... [+9]